Pretreatment neutrophil-lymphocyte ratio and platelet-lymphocyte ratio as prognostic biomarkers for neuroblastoma risk stratification - Takeaways - MDSpire

Pretreatment neutrophil-lymphocyte ratio and platelet-lymphocyte ratio as prognostic biomarkers for neuroblastoma risk stratification

  • By

  • Lixiao Shi

  • Dixiao Zhong

  • Ruihong Tang

  • Duanfang Shao

  • Xiang Cheng

  • Zhaoxia Zhang

  • Rong Liu

  • June 15, 2026

  • 0 min

Share

  • 1

    Neuroblastoma is the most common extracranial solid tumor in children, contributing to 15% of pediatric oncology mortality.

  • 2

    Pretreatment NLR and PLR are significant prognostic biomarkers for risk stratification in neuroblastoma patients.

  • 3

    Optimal cutoff values for NLR and PLR were established at 0.98 and 104.6, respectively, for differentiating risk levels.

  • 4

    Patients with elevated NLR and PLR are more likely to present with advanced disease stages compared to lower-risk patients.

  • 5

    Incorporating NLR and PLR into standard protocols may enhance the precision of neuroblastoma risk stratification.

Original Source(s)

Pretreatment neutrophil-lymphocyte ratio and platelet-lymphocyte ratio as prognostic biomarkers for neuroblastoma risk stratification

  • by Lixiao Shi, Dixiao Zhong, Ruihong Tang, Duanfang Shao, Xiang Cheng, Zhaoxia Zhang, Rong Liu

  • June 15, 2026

Related Content

Clinicopathologic features and integrated outcome analysis of pediatric and young adult salivary secretory carcinoma

Conditional survival analysis May enhance prognosis estimate in buccal mucosa carcinoma

p53-associated regulation of COX17 enhances elesclomol-induced copper-associated cytotoxicity and suppresses gastric cancer growth